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determinants of improvement in pain and function included age,
mental function score of the SF-12 and pre-operative pain and function
(both pain and function), as well as gender and BMI (function only).
Conclusions: The data suggest that we should exercise caution when
considering surgery for patients with severe pain but mild radio-
graphic changes, and conversely, that those with severe joint
damage, irrespective of which compartments are involved, are more
likely to respond well to surgery. A possible explanation for this is
that in those with severe pain and mild joint damage the pain is
driven more by central sensitisation than by any nociceptive input
from the joint.
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A 2-YEAR RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,
MULTICENTER STUDY OF AN ORAL SELECTIVE INOS INHIBITOR IN
SUBJECTS WITH SYMPTOMATIC OSTEOARTHRITIS OF THE KNEE
M.-P. Hellio le Graverand-Gastineau 1, R. Clemmer 1, P. Redifer 1,
R.M. Brunell 1, C.W. Hayes 2, K. Brandt 3, S.B. Abramson 4,
P.T. Manning 5, C.G. Miller 6, E. Vignon 7. 1 Pﬁzer Inc, Primary Care
Med.s Dev. Group, Groton, CT, USA; 2Virginia Commonwealth Univ.
Hlth.System, Richmond, VA, USA; 3Kansas Univ. Med. Ctr., Kansas City,
KS, USA; 4New York Sch. of Med., New York, NY, USA; 5Vasculox, Inc, St
Louis, MO, USA; 6BioClinica Inc, Newtown, PA, USA; 7Claude Bernard
Univ., Lyon, France
Purpose: To determine whether inhibition of inducible nitric oxide
synthase (iNOS) can slow progression of knee osteoarthritis (OA), using
the rate of joint space narrowing (JSN) in the medial tibiofemoral
compartment as the primary outcome measure.
Methods: This was a 2-year multinational, multicenter, double-blind,
parallel group trial enrolling subjects with symptomatic knee OA in
which subjects were randomly assigned to receive once daily 50 mg or
200 mg of the selective iNOS inhibitor, SD-6010, or placebo. Subjects
were required to have a bodymass index (BMI)25 and 40 kg/m2 and
Kellgren and Lawrence Grade (KLG) 2 or 3 in the study knee.
Randomization was stratiﬁed by KLG. Radiographs were acquired using
the modiﬁed Lyon-schuss protocol, at baseline, 48 and 96 weeks for
measuring JSN. Clinical beneﬁt was recorded at 12-week then every 24
weeks; use of acetaminophen, NSAIDs and/or weak opioids was
permitted throughout the trial. The primary analysis of the rate of JSN
used a continuous time random coefﬁcients MMRM model. The slope
over the entire 96 week period was used to assess the rate of change in
joint space width (JSW).
Results: Of 1457 randomized subjects (SD-6010 50mg, n¼485; SD-6010
200mg, n¼486; placebo, n¼486), 1048 (71.9%) completed the study.
Subjects were predominantly female (76.5%) with mean age 61.
0 years and mean BMI of 31.8 kg/m2. Fifty-six percent had KLG3. The
primary analysis did not demonstrate the superiority of SD-6010 in
either treatment group over placebo. In an exploratory discrete time
MMRM analysis of KLG2 subjects, the loss of JSW after 48 weeks was
signiﬁcantly smaller with SD-6010 (50 mg or 200 mg) than placebo.
Least squared (LS) mean  standard error (SE) losses in JSW for SD-
6010 50mg (-0.048  0.028 mm) and 200mg (-0.062  0.028 mm)
were 59.9% (95% CI: 6.8%, 106.9%) and 48.7% (95% CI: -8.4%, 93.9%) of
placebo (-0.120  0.028 mm; P¼0.032 and P¼0.081, respectively).
After 96 weeks, the LS mean losses in JSW for SD-6010 50mg (-0.132
 0.036 mm) and 200mg (-0.156  0.037 mm) were 20.9% (95% CI:
-50.5%, 64.0%) and 6.8% (95% CI: -72.7%, 51.7%) of the LS-mean JSW
loss in the placebo group (-0.1670.036 mm) (P¼0.460 and P¼0.812,
respectively). In a similar analysis of KLG3 subjects, no improvement
in JSN was observed. Although SD-6010 showed no efﬁcacy with
respect to improvement in joint pain or function, it was generally safe
and well tolerated in this population.
Conclusions:During the ﬁrst 48 weeks of treatment, subjects with mild
OA who were treated with an iNOS inhibitor had a lower rate of JSN;
however, this improvement was not sustained at 96 weeks. iNOS
inhibition did not slow OA progression in subjects with more severe
radiographic OA. The observed early effect on JSN in subjects with mild
OA supports the role of iNOS in OA pathogenetic mechanisms. However,
the loss of efﬁcacy over time and the lack of effect in subjects with more
severe disease suggest that alternative biochemical catabolic pathways
overcame the effects of nitric oxide inhibition alone or that in more
severe radiographic OA, biomechanical factors may not be amenable to
iNOS inhibition.57
INFLAMMATORY BIOMARKERS OF OA, IL-6 AND LEPTIN ARE
MODIFIABLE IN OVERWEIGHT/OBESE OA PATIENTS WITH
A PROTOCOL THAT COMBINES TRAINING IN PAIN COPING SKILLS
AND WEIGHT MANAGEMENT
J.L. Huebner, L.R. Landerman, T.J. Somers, V.B. Kraus, F. Guilak,
J.A. Blumenthal, D.S. Caldwell, J.R. Rice, F.J. Keefe. Duke Univ. Med. Ctr.,
Durham, NC, USA
Purpose: A randomized clinical trial to investigate the effect of
a combined pain coping skills training and lifestyle behavioral weight
management protocol, on knee pain and disability as well as systemic
biochemical markers, in overweight and obese patients with knee
osteoarthritis.
Methods: Eligibility for the OA LIFE study enrolled participants with
self-reported knee pain who were overweight or obese, met the ACR
criteria for knee OA, and had radiographic evidence of OA in at least one
knee. A total of 232 participants were enrolled in the study and
randomized to one of four treatment groups:1) pain coping skills
training alone (PCST-only), 2) behavioral weight loss alone (BWL-only)
3) PCST with BWL (PCST+BWL), or 4) standard care control (SC). Blood
and urine were collected for biomarker analyses and questionnaires
obtained to assess pain, physical disability, stiffness, activity, psycho-
logical disability (WOMAC, AIMS). Following a 24 week treatment
period, 63 of the participants dropped out prior to completing the
treatment protocol. The remaining 169 subjects completed a post-
treatment clinical assessment and biospecimen collection. Samples
were analyzed for inﬂammatorymarkers (hsCRP, IL-1ra, IL-1b, IL-6, IL-8,
TNF-a, TNFR1 and TNFRII), adipokines (leptin and adiponectin), and
joint biomarkers (HA) by immunoassay. Data are reported as mean (SD)
and theWilcoxon test used to compare biomarker levels at baseline and
after treatment. Values for cytokines were log transformed and corre-
lations were tested with Pearson correlation test. Multivariable
regression analysis was used to assess the effects of treatment group on
the change in biomarker levels during treatment and adjusted for age,
race, gender, and BMI. All analyses were performed using SAS and a p
value of <0.05 was considered statistically signiﬁcant.
Results: Our study population consisted of 169 overweight or obese
patients who were 83% female, 60% white, having a mean (SD) age of
58.70 (10.0) years and a mean (SD) BMI of 34.10 (4.42) at baseline. As
reported previously, patients randomized to PCST+ BWM demonstrated
signiﬁcantly better treatment outcomes in terms of pain and weight
loss when compared to the other three conditions (p¼ <0.05). Analyses
conducted for the present paper comparing mean biomarker levels
before and after treatment revealed signiﬁcant reductions in levels of
hsCRP (p¼0.0014), IL-6 (p¼0.0075), and leptin (p¼0.0001) for the
combined intervention group (PCST+BWL). Adjusting for age, race,
gender, BMI, and baseline biomarker concentration, there were signif-
icant reductions in leptin (b¼-0.19175, p¼0.0120) and IL-6 (b¼-0.25036,
p¼0.0232) in response to only the combined PCST+BWL treatment.
Reductions in both IL-6 and leptin, regardless of the treatment group,
were signiﬁcantly associated with a reduction in WOMAC pain scores.
Changes in IL-6 were also signiﬁcantly associated with changes in
WOMAC physical function score (r¼0.198, p¼0.014) and AIMS physical
disability score (r¼0.192, p¼0.018) and changes in leptin were signiﬁ-
cantly associated with changes in AIMS pain score (r¼0.165, p¼0.040).
Conclusions: This is the ﬁrst study to investigate the effects of
combined pain coping skills training and behavioral weight manage-
ment protocol on biomarkers of inﬂammation in overweight and obese
OA patients. Participants receiving this protocol were not only
successful in signiﬁcantly reducing their pain and weight, but this was
accompanied by signiﬁcant reductions in inﬂammatory markers with
known associations with OA severity. The signiﬁcant reduction in
weight experienced by the combined treatment group is likely the
source of the changes in inﬂammatory state, as adipose tissue is
a known source of inﬂammatory cytokines/adipokines, such as IL-6 and
leptin. This study demonstrated that this inﬂammatory state can be
successfully modiﬁed with behavioral intervention resulting in positive
clinical outcomes.
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ABNORMAL PROCESSING OF TYPE II COLLAGEN IN CARTILAGE-
SPECIFIC SITE-1 PROTEASE KNOCKOUT MICE
D. Patra, E. DeLassus, J. Mueller, L.J. Sandell. Washington Univ. Sch. of
Med., St. Louis, MO, USA
Abstracts / Osteoarthritis and Cartilage 20 (2012) S10–S53 S39Purpose: Site-1 protease (S1P) is a proprotein convertase that is
primarily known for processing of latent, endoplasmic reticulum (ER)
membrane-bound transcription factors SREBPs and ATF6 to their free
and active form. SREBPs are involved in cholesterol and fatty acid
homeostasis; ATF6 is involved in ER stress response. Cartilage-
speciﬁc knockout of S1P in mice (S1Pcko) results in poor cartilage
with a drastic decrease of collagen type IIB (Col IIB) in the matrix
and a complete lack of endochondral bone formation. Ultrastructural
analysis of the cartilage shows engorged and fragmented ER
characteristic of ER stress. S1Pcko chondrocytes would be expected to
lack both active SREBPs and ATF6 proteins. The goal of this study is
to identify the requirement of SREBPs- and ATF6-related pathways
for normal Col IIB deposition in the cartilage
Methods: RNAwas extracted from the cartilage of E16.5 S1Pcko and wild
type (WT) littermates followed by genome-wide expression proﬁling
using Illumina MouseWG-6 v2 Expression BeadChip, and differential
gene expression was analyzed by 2-way ANOVA. The expression
proﬁling was further conﬁrmed by qPCR. Col IIB processing in S1Pcko
mice was analyzed by immunoﬂuorescence. Knockout mouse models
of genes down-regulated in S1Pcko chondrocytes were analyzed for Col
IIB deposition. Cartilage-speciﬁc deletion of S1P was also analyzed
temporally in a postnatal S1P ablation model via in situ hybridization
and immunoﬂuorescence to follow the relationship between S1P
ablation and Col IIB entrapment in chondrocytes.
Results: Genome-wide expression proﬁling followed by qPCR analyses
demonstrated that ATF6-directed ER stress response was normal in
S1Pcko mice. However, fatty acid and cholesterol synthesis was down-
regulated in S1Pcko with the largest reduction seen in expression of
stearoyl-CoA desaturase 1 (Scd1) gene. However, Scd1-/- knockout
mice did not display any defects in Col IIB deposition. Double labeled
immunoﬂuorescence analysis demonstrated the retention of Col IIB in
the ER of S1Pcko chondrocytes, but not that of COMP and aggrecan.
Temporal studies with postnatal S1P ablation demonstrated that Col
IIB retention inside the chondrocyte is almost immediate on S1P
ablation, which was followed later by chondrocyte apoptosis. In
double-labeled immunoﬂuorescence studies targeting Col IIB triple
helical domain and the Col II N-propeptide, the WT exhibited signals
from the triple helical domain primarily in the matrix and those from
the N-propeptide inside the cell. In S1Pcko however, signals from the
triple helical domain and the N-propeptide overlapped inside the cell,
suggesting abnormal processing of the Col IIB protein. Western
blotting for the Col II N-proteinase ADAMTS3 demonstrated the
retention of ADAMTS3 in S1Pcko chondrocytes that was not seen in WT
cells
Conclusions: Our studies demonstrated that S1P plays a pivotal role,
direct or indirect, in Col IIB maturation. The retention of Col II
N-terminus and Col IIB triple helical domain along with ADAMTS3 in
S1Pcko chondrocytes indicates a role for S1P in Col IIB processing, in the
absence of which chondrocytes are unable to secrete Col IIB into the
matrix. Even though cholesterol and lipid homeostasis pathways are
down-regulated in S1Pcko, the lack of any bone or cartilage phenotype
in Scd1-/- knockout mice suggests that S1P does not play this role via
SREBP processing. As ATF6-related pathways are not down-regulated
in S1Pcko and ER stress response was secondary to Col IIB retention,
ATF6-related pathways are not the primary cause for Col IIB anomalies.
These data along with the retention of ADAMTS3 in S1Pcko
chondrocytes suggest additional proprotein convertase activities for
S1P, besides transcription factor processing, that are essential for Col
IIB processing and cartilage development.
59
INORGANIC POLYPHOSPHATE EXHIBITS ANABOLIC EFFECTS ON
ARTICULAR CARTILAGE
J.-P. St-Pierre, J.N. De Croos, J.S. Theodoropoulos, M. Petrera, P. Sharma,
S. Li, R.M. Pilliar, M.D. Grynpas, R.A. Kandel. CIHR-BioEngineering of
Skeletal Tissues Team, Mount Sinai Hosp. and Univ. of Toronto, Toronto,
ON, Canada
Purpose: Osteoarthritis (OA) is a group of diseases characterized by the
loss of articular cartilage as a result of an imbalance between anabolic
and catabolic processes, as well as tissue calciﬁcation. Current OA
therapies aim to reduce symptoms but do notmodify the progression of
the disease. Inorganic polyphosphate (PP) is a linear polymer of
orthophosphate residues linked by energy-rich phosphoanhydride
bonds. It is found ubiquitously in biological systems from bacteria toanimal cells and is present in relatively large quantities in articular
cartilage and bone. PP is known to inhibit tissue calciﬁcation. The
purpose of this study was to determine if PP treatment would have an
anabolic effect on cartilage. This was evaluated both in vitro and in vivo.
Methods: Articular cartilage was obtained from bovine metacarpal-
phalangeal joints and either maintained in explant culture or used for
chondrocyte isolation. Cells harvested by enzymatic digestion were
seeded on membrane inserts (1x106 cells/insert). The 3D cultures were
maintained under standard tissue culture conditions in the presence or
absence of PP for various times up to 4 weeks. Resulting tissues were
analyzed for DNA, glycosaminoglycan (GAG) and collagen synthesis and
accumulation, gene expression and exopolyphosphatase activity. Full
thickness cartilage explants were treated similarly but harvested after 1
week. To evaluate the effect of PP on the progression of OA, left-medial
menisectomy was performed on the knee of 20 male Hartley guinea
pigs (3 months of age). Starting the day following surgery, the animals
received biweekly intra-articular injections (100ml) of either: 1) 4mM
PP in PBS, or 2) PBS alone (10 animals/ condition). After 2 months, the
animals were sacriﬁced and the joints, following decalciﬁcation and
parafﬁn embedding, were evaluated histologically using the OARSI
guinea pig grading scale.
Results: PP stimulated GAG and collagen accumulation by chondrocytes
in a concentration and chain length dependent manner. The optimal PP
chain length for matrix accumulation was 45 phosphate units. This
effect of PP on matrix accumulation was reversible as exopolyphos-
phatases were produced by chondrocytes that can cleave the end
phosphate of PP chains. Similar concentrations (on a phosphate basis) of
orthophosphate and inorganic pyrophosphate had no effect on matrix
accumulation by chondrocytes. Collagen type II, aggrecan and sox9 gene
expression were not altered by the PP treatment but proteoglycan and
collagen synthesis were both signiﬁcantly increased by the treatment. A
time course study demonstrated increased DNA content in cultures
treated with PP with time, albeit at a decreased rate compared to
untreated cultures. Cartilage explants responded similarly to PP treat-
ment as the chondrocyte cultures. Intra-articular injections of PP were
chondroprotective as the histological OA score was signiﬁcantly
decreased in the treated OA guinea pig model compared to that of
animals treated with the PBS carrier (PP treated: 7.4  3.09; Carrier:
16.9  3.55; p<0.05; Mann-Whitney test; n¼10).
Conclusions: PP was shown to be chondroprotective in a menisectom-
ized guinea pig model of OA. In vitro studies suggest this effect is
mediated at least in part by stimulating matrix production by chon-
drocytes. Further study is ongoing to optimize PP delivery in vivo.
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SECOND GENERATION CHARACTERIZED CHONDROCYTE
IMPLANTATION FOR THE TREATMENT OF CARTILAGE LESIONS IN
THE KNEE
A.A. Dhollander, P.C. Verdonk, S. Lambrecht, R. Verdonk, D. Elewaut,
G. Verbruggen, F. Almqvist. Ghent Univ., Ghent, Belgium
Purpose: To evaluate short-term clinical and MRI outcome of the
second generation characterized chondrocyte implantation (CCI) for the
treatment of cartilage defects in the knee.
Methods: Thirty-two patients aged 15-51 years with sin- gle Interna-
tional Cartilage Repair Society (ICRS) grade III/ IV symptomatic cartilage
defects of different locations in the knee were treated with CCI using
a synthetic collagen I/III membrane to cover the defect. Clinical outcome
was measured over 36 months by the Knee injury and Osteoarthritis
Outcome Score (KOOS) and Visual Analogue Scale (VAS) for pain. Serial
magnetic resonance imaging (MRI) scans of 22 patients were scored
using the original and modiﬁed Magnetic resonance Observation of
Cartilage Repair Tissue (MOCART) system.
Results: The patients included in this study showed a signiﬁcant
gradual clinical improvement after CCI. The MRI ﬁndings of this pilot
study were considered to be promising. No signs of deterioration were
observed. A complete or hypertrophic ﬁlling was observed in 76.5% of
the cases at 24 months of follow-up. No preventive effect of an avital
membrane on the occurrence of hypertrophic repair tissue was
observed on MRI. Three failures were observed among the 32 patients
until now (9.4%).
Conclusions: This investigation provided useful information on the
efﬁcacy of this treatment. The short-term clinical and MRI outcome are
promising. Large-scale and long-term trials are mandatory to conﬁrm
the results and the reliability of this procedure.
